Jesse McClelland, MD
Psychiatry · Seattle, WANPI 1033395587
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Ironshore Pharmaceuticals Inc. accounts for 92.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $18,562 and has fallen 99.0% since, to $184 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $140.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$36K
- AbbVie$673
- Supernus Pharmaceuticals, Inc.$655
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$418
- Tris Pharma Inc$337
- Bausch Health US, LLC$334
- plus $632 from 11 others
What the payments were for
- Consulting fees$9,40124%
- Speaking & faculty fees$19,64050%
- Travel & lodging$4,18411%
- Food & beverage$5,97315%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 93 | $36,194 |
| AbbVie(2 entities) | 39 | $673 |
| Supernus Pharmaceuticals, Inc. | 55 | $655 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $418 |
| Tris Pharma Inc | 14 | $337 |
| Bausch Health US, LLC | 22 | $334 |
| Otsuka America Pharmaceutical, Inc. | 10 | $167 |
| Avanir Pharmaceuticals, Inc. | 7 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $131 |
| Adlon Therapeutics L.p. | 2 | $38 |
| Lundbeck LLC | 2 | $37 |
| Eisai Inc. | 1 | $24 |
| Corium, LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$17,744
- JORNAY PM$16,730
- QELBREE$147
- Dyanavel XR$122
- Quillivant$122
- Quillichew ER$122
How this compares
$39,244 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 30 | $3,993 |
| Methylphenidate ErMethylphenidate Hcl | 13 | $2,991 |
| Dextroamphetamine Sulfate | 20 | $716 |
| Guanfacine Hcl | 13 | $570 |
| Alprazolam | 12 | $94 |
| Zolpidem Tartrate | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Seattle
- Chester RobachinskiSeattle$1.1M
- Pablo ProanoSeattle$112K
- Lina FineSeattle$30K
- Jonathan BuchholzSeattle$7K
- Steven MitchellSeattle$7K
- Randall EspinozaSeattle$6K
- John KernSeattle$6K
- James BowenSeattle$4K
- Gerard ZanolliSeattle$3K
- Shahm MartiniSeattle$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.